



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/696,900	10/30/2003	James M. Wilson	K1774CON	1181

270 7590 06/14/2005

HOWSON AND HOWSON
ONE SPRING HOUSE CORPORATION CENTER
BOX 457
321 NORRISTOWN ROAD
SPRING HOUSE, PA 19477

EXAMINER

WHITEMAN, BRIAN A

ART UNIT	PAPER NUMBER
----------	--------------

1635

DATE MAILED: 06/14/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/696,900	Applicant(s) WILSON ET AL.	
	Examiner Brian Whiteman	Art Unit 1635	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-22 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-22 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____. | 6) <input checked="" type="checkbox"/> Other: <u>Notice to Comply</u> . |

DETAILED ACTION

Claims 1-22 are pending.

This application contains sequence disclosures that are encompassed by the definition for nucleotide sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements for Patent Applications Containing Nucleotide Sequence Disclosures.

There are nucleotide sequences in Figures 2 and 3B and the sequences are missing a corresponding SEQ ID NO. The nucleotide sequences appear to be in the CRF.

Claim 8 is withdrawn from the election/restriction because the claims is missing an active step because the preamble of the claim is directed to producing a selected gene product in a mammalian cell and the body of the claim does not recite a nucleic acid encoding the gene product. The only product required in the instant claim is an isolated AAV-1 nucleic acid molecule that does not comprise a nucleic acid encoding a gene product. Thus, the examiner cannot determine whether the method is directed to producing AAV-1 nucleic acid or a nucleic acid encoding a gene product and if the claim belongs in Group III or a separate group. If the claim is amended to complete the preamble of the claim in the response to the election/restriction, then at that time the examiner will determine whether or not the claim reads on the elected invention or a non-elected invention.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-2 and 12-13, drawn to an isolated AAV-1 nucleic acid molecule comprising a sequence consisting of SEQ ID NO: 1, classifiable in class 536, subclass 23.72.
- II. Claims 3-6, 9-11 and 17-22, drawn to a recombinant vector comprising a 5' AAV-1 ITR and a selected transgene, classifiable in class 435, subclass 320.1.
- III. Claims 7, 14, and 15, drawn to a method for producing a transgene in a cell comprising administering a virus comprising a vector comprising a 3' AAV-1 ITR and a selected transgene and a pharmaceutical composition comprising the virus, classifiable in class 424, subclass 93.2.
- IV. Claim 16, drawn to a recombinant host cell comprising a nucleic acid sequence expressing one or more AAV-1 rep proteins selected from SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, classifiable in class 435, subclass 325.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II-IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). The instant specification does not disclose that the isolated AAV-1 molecule in Group I is capable of use together with the inventions set forth in Groups II-IV. The isolated AAV-1 molecule in Group I does not require a transgene or one or more AAV-1 rep proteins. The method in Group III does not require the product of Group I. Furthermore, the information provided by the nucleic acid molecule of Group I can be used to make a materially different nucleic acid molecule than that used in Groups II-IV. For example, a nucleic acid which hybridizes to SEQ ID NO: 1 encompasses molecules which

contain point mutations, splice sites, frameshift mutations, or stop codons which would result in use of a different open reading frame, and this encode a protein that lacks any significant structure in common with the nucleic sequence in Groups II-IV. Furthermore, searching the inventions of Groups I and II-IV together would impose a serious search burden. In the instant case, the search of the nucleic acid molecule in Group I and the nucleic acid in Groups II-IV are not coextensive. The inventions of Group I and Groups II-IV have a separate search status as shown by their different classifications. In cases such as this one where descriptive sequence information is provided, the sequences are searched in appropriate databases. There is a search burden also in the non-patent literature. Prior to the concomitant isolation and expression of the sequence of interest there may be journal articles devoted solely to the isolated nucleic acid molecule which would not describe the nucleic acid molecule in Groups II-IV. Searching, therefore is not coextensive. In addition, the nucleic acid molecule include a DNA or RNA complementary to SEQ ID NO: 1. This search requires an extensive analysis of technical literature. The scope of the nucleic acid molecule as claimed extend beyond the isolated AAV-1 nucleic acid molecule as explained above; furthermore a search of the nucleic acid molecule of claim 1(b)-(d) would require an oligonucleotide search, which is not likely to result in relevant art with respect to the nucleic acid molecule in Groups II-IV. As such, it would be burdensome to search the inventions of groups I and II-IV together. For these reasons the Inventions of I and II-IV are patentably distinct.

Invention II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product

Art Unit: 1635

as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the virus comprising the vector can be used to make recombinant proteins in vivo or in vitro or a virus comprising a chimeric vector. Searching the inventions of Groups II and III together would impose serious search burden because the inventions II and III have a separate search status in the art as shown by their different classifications. Moreover, even if the virus product were known, the method of delivering a transgene to a host cell may be novel and unobvious in view of the preamble or active steps.

Inventions II and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). The instant specification does not disclose that the inventions are capable of use together. The recombinant host cell in Invention IV is not required for use in the virus in Invention II. The inventions II and IV have a separate search status in the art as shown by their different classifications. A search for a recombinant host cell transformed with a nucleic acid sequence expressing one or more AAV-1 rep proteins would not overlap with a search for a recombinant vector comprising a 5' AAV-1 ITR and a selected transgene. For these reasons the Inventions of II and IV are patentably distinct.

Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant specification does not disclose that the inventions are capable of use together. The recombinant host cell in Invention IV is not required for use in the method in Invention III. The inventions III and IV

Art Unit: 1635

have a separate search status in the art as shown by their different classifications. A search for a recombinant host cell transformed with a nucleic acid sequence expressing one or more AAV-1 rep proteins would not overlap with a search for delivering a transgene using a recombinant AAV-1 virus. For these reasons the Inventions of III and IV are patentably distinct.

Because these inventions are distinct for the reasons given above and the search required for each Group listed above is not required for any other Group listed above and the search for each group is not co-extensive, restriction for examination purposes as indicated is proper.

It would be unduly burdensome for the examiner to search and consider patentability of all of the presently pending claims, a restriction for examination purposes as indicated is proper.

If applicants elect Group II, applicants are required to elect a species from the following:

This application contains claims directed to the following patentably distinct species of the claimed invention: recombinant virus having an AAV-1 capsid comprising an AAV-1 protein selected from among AAV-1 vp1 (SEQ ID NO: 13), AAV-1 vp2 (SEQ ID NO: 15), and AAV-1 vp3 (SEQ ID NO: 17).

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 9 and 17 are generic.

If applicants elect Group IV, applicants are required to elect a species from the following:

This application contains claims directed to the following patentably distinct species of the claimed invention: a nucleic acid expressing one or more AAV-1 rep proteins selected from among rep78, rep68, rep52, and rep40.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Applicant is required to elect a specific combination (e.g., one rep protein (e.g., rep78) or a combination of rep proteins (e.g., rep78 and rep52). Currently, claim 16 is generic. It is noted that rep78 and rep68 have the same SEQ ID NO (SEQ ID NO: 7).

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the

Art Unit: 1635

product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 § 1.17(h).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Whiteman whose telephone number is (571) 272-0764. The examiner can normally be reached on Monday through Friday from 7:00 to 4:00 (Eastern Standard Time), with alternating Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang, acting SPE - Art Unit 1635, can be reached at (571) 272-0811.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal

Art Unit: 1635

Mall 1. The faxing of such papers must conform with the notice published in the Official


Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center number is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Brian Whiteman
1635

A handwritten signature in cursive script, appearing to read "Brian Whiteman", written in dark ink.

Notice to Comply	Application No. 10/696,900	Applicant(s) Wilson et al.	
	Examiner B. Whiteman	Art Unit 1635	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Seq ID No is missing for the nucleotide sequences in Fig 2 and Fig. 3B.

Applicant Must Provide:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the specification.**
- ☐ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510

For CRF Submission Help, call (571) 272-2501/2583.

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY